This study is testing a combination treatment for high-risk superficial upper urinary tract transitional cell carcinoma (UUTTCC), a type of cancer in the upper urinary tract. You might be eligible if you have this type of cancer that can be removed with an endoscopic procedure (a procedure using a thin, lighted tube) and you are unable or unwilling to have a radical nephroureterectomy (surgery to remove the kidney and ureter). The study is looking at the safety of Pembrolizumab (also known as MK-3475) when given with BCG, a common treatment for this cancer, after your cancer has been removed. The main goal is to see if this combination leads to a complete response, meaning no signs of cancer, as checked by a scope and tissue samples at 19 weeks. The current recruitment status is unclear, and the study plans to enroll 20 participants.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 20 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 19 weeks, which suggests follow-up for at least this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.